Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

<p>HRR gene mutations found in WGS/WES or clinical BRCA1/2 mutational testing.</p>

保存先:

書誌詳細
第一著者:	Sanna Pikkusaari (15055802) (author)
その他の著者:	Manuela Tumiati (15011915) (author), Anni Virtanen (15055805) (author), Jaana Oikkonen (14948281) (author), Yilin Li (15055808) (author), Fernando Perez-Villatoro (15055811) (author), Taru Muranen (15055814) (author), Matilda Salko (15055817) (author), Kaisa Huhtinen (15055820) (author), Anna Kanerva (15055823) (author), Heidi Koskela (15055826) (author), Johanna Tapper (15055829) (author), Riitta Koivisto-Korander (15055832) (author), Titta Joutsiniemi (15055835) (author), Ulla-Maija Haltia (15055838) (author), Heini Lassus (15055841) (author), Sampsa Hautaniemi (14948308) (author), Anniina Färkkilä (14948278) (author), Johanna Hynninen (14932815) (author), Sakari Hietanen (14932818) (author), Olli Carpén (14932812) (author), Liisa Kauppi (15055844) (author)
出版事項:	2025
主題:	Cancer Molecular and Cellular Biology Cancer Detection and Diagnosis Therapeutic Research and Development Clinical Research and Trials Biomarkers Prognostic biomarkers Chemotherapy DNA Damage and Repair Drug Resistance Clinical drug resistance Gynecological Cancers Ovarian cancer Precision Medicine
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
著者:: Sanna Pikkusaari (15055802)
出版事項: (2025)

Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
著者:: Stephanie L. Wethington (16354020)
出版事項: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
著者:: Arun Kanakkanthara (14937731)
出版事項: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
著者:: Arun Kanakkanthara (14937731)
出版事項: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
著者:: Chong Kin Liam (15331321)
出版事項: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
著者:: Chong Kin Liam (15331321)
出版事項: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
著者:: Chong Kin Liam (15331321)
出版事項: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
著者:: Chong Kin Liam (15331321)
出版事項: (2025)

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer
著者:: Jiachun Su (16990970)
出版事項: (2025)

Supplementary Table from CircIPO7 Promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by Facilitating YBX1 Nuclear Localization
著者:: Xiaohong Hong (22681698)
出版事項: (2025)

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
著者:: Seung Yeon Oh (15051017)
出版事項: (2025)

Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
著者:: Seung Yeon Oh (15051017)
出版事項: (2025)

Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
著者:: Seung Yeon Oh (15051017)
出版事項: (2025)

Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
著者:: Seung Yeon Oh (15051017)
出版事項: (2025)

Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
著者:: Seung Yeon Oh (15051017)
出版事項: (2025)

Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
著者:: Seung Yeon Oh (15051017)
出版事項: (2025)

Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
著者:: Seung Yeon Oh (15051017)
出版事項: (2025)

Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
著者:: Seung Yeon Oh (15051017)
出版事項: (2025)

Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
著者:: Seung Yeon Oh (15051017)
出版事項: (2025)

Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
著者:: Seung Yeon Oh (15051017)
出版事項: (2025)

Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
著者:: Seung Yeon Oh (15051017)
出版事項: (2025)

Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
著者:: Seung Yeon Oh (15051017)
出版事項: (2025)

Supplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
著者:: Kavya Ramkumar (16474203)
出版事項: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
著者:: Alex C.H. Liu (14961921)
出版事項: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
著者:: Alex C.H. Liu (14961921)
出版事項: (2025)

Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
著者:: Alex C.H. Liu (14961921)
出版事項: (2025)

Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
著者:: Alex C.H. Liu (14961921)
出版事項: (2025)

Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
著者:: Alex C.H. Liu (14961921)
出版事項: (2025)

Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
著者:: Alex C.H. Liu (14961921)
出版事項: (2025)

Supplementary Table S1 from Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma
著者:: Phyllis S.Y. Chong (17141520)
出版事項: (2025)

Supplementary Table S2 from Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma
著者:: Phyllis S.Y. Chong (17141520)
出版事項: (2025)

Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
著者:: Milana A. Bergamino (15038015)
出版事項: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
著者:: Milana A. Bergamino (15038015)
出版事項: (2025)

Figure 3 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
著者:: Milana A. Bergamino (15038015)
出版事項: (2025)

Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
著者:: Milana A. Bergamino (15038015)
出版事項: (2025)

Figure 5 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
著者:: Milana A. Bergamino (15038015)
出版事項: (2025)

Figure 6 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
著者:: Milana A. Bergamino (15038015)
出版事項: (2025)

Movie S1 from Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics
著者:: Jill Gallaher (16799594)
出版事項: (2025)

Movie S2 from Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics
著者:: Jill Gallaher (16799594)
出版事項: (2025)

Movie S3 from Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics
著者:: Jill Gallaher (16799594)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_k9g75usqeanq1hbf093hs87815